Type 2 Diabetes Market Summary

• Type 2 Diabetes is a chronic metabolic disorder marked by insulin resistance and progressive ß-cell dysfunction, leading to persistent hyperglycemia. Unlike type 1 diabetes, Type 2 Diabetes develops primarily from impaired insulin action, initially compensated by increased insulin secretion until ß-cell failure occurs. Its global rise is driven by aging populations and lifestyle changes such as physical inactivity and high-calorie diets, contributing to significant microvascular and macrovascular complications.
• Type 2 diabetes can develop at any age, including during childhood, but it is more common among middle-aged and older adults. The risk increases with age, particularly after 45 years, as well as with a family history of diabetes and overweight or obesity.
• More than 40 million Americans have diabetes, equivalent to approximately 1 in 8 people, and around 90%–95% of these individuals have type 2 diabetes. Type 2 diabetes most commonly develops in people aged 45 years and older; however, an increasing number of children, adolescents, and young adults are also developing the condition.
• GLP-1 may play a broader cardiometabolic role beyond glucose control, with GLP-1 receptor signaling potentially contributing to blood pressure regulation and sympathetic activity, thereby highlighting the potential of GLP-1–based therapies to address both glycemic control and cardiovascular risk factors.
• Real-world evidence highlights a significant GLP-1 therapy adherence challenge, with up to 64% of patients discontinuing treatment within 1 year and 74% by year 2, underscoring the need for more convenient oral alternatives that could reduce injection burden and potentially improve long-term treatment persistence.
• The Type 2 Diabetes GLP-1 pipeline includes promising next-generation candidates such as retatrutide (Eli Lilly), CagriSema (Novo Nordisk), and survodutide (Boehringer Ingelheim), among others. By leveraging multi-receptor agonism and complementary metabolic pathways, these therapies aim to deliver enhanced glycemic control, weight-loss efficacy, and broader cardiometabolic benefits, potentially addressing key unmet needs in Type 2 Diabetes management.
• The marketed Type 2 Diabetes therapies include semaglutide (OZEMPIC, RYBELSUS), liraglutide (VICTOZA), dulaglutide (TRULICITY), tirzepatide (MOUNJARO), empagliflozin (JARDIANCE), dapagliflozin (FARXIGA), canagliflozin (INVOKANA), sitagliptin (JANUVIA), linagliptin (TRADJENTA), and saxagliptin (ONGLYZA). These therapies provide established glycemic control, with several also demonstrating weight-management, cardiovascular, and kidney-related benefits, supporting their continued use across the evolving Type 2 Diabetes treatment landscape.

Type 2 Diabetes Market Size and Forecast in the 7MM

• 2025 Type 2 Diabetes Market Size: ~USD XXXX million
• 2026 Type 2 Diabetes Market Size: ~USD XXXX million
• Type 2 Diabetes Growth Rate (2026–2036): ~XX% CAGR

DelveInsight's "Type 2 Diabetes Market Insights, Epidemiology and Market Forecast – 2036" report delivers an in-depth understanding of the Type 2 Diabetes, historical and forecasted epidemiology, as well as the Type 2 Diabetes market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Type 2 Diabetes market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, Type 2 Diabetes patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022–2036) across global regions. The report highlights key unmet medical needs in Type 2 Diabetes and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Type 2 Diabetes Market

• Rising Type 2 Diabetes Prevalence: The increasing prevalence of Type 2 Diabetes is a key driver of Type 2 Diabetes market expansion, supported by rising obesity rates, sedentary lifestyles, aging populations, increasing disease awareness and diagnosis, and growing adoption of newer therapies that provide effective glycemic control alongside weight-management, cardiovascular, and kidney benefits.
• Rising Opportunities in Novel Type 2 Diabetes Therapies: The substantial unmet need in Type 2 Diabetes is creating opportunities for next-generation therapies, oral treatment options, and multi-target metabolic approaches aimed at improving glycemic control, supporting sustained weight loss, reducing cardiovascular and kidney-related complications, and enhancing treatment adherence, thereby addressing limitations associated with conventional Type 2 Diabetes therapies.

Type 2 Diabetes Disease Understanding

Type 2 Diabetes Overview

Type 2 Diabetes is a chronic, progressive metabolic disorder characterized by insulin resistance and inadequate insulin secretion, resulting in persistently elevated blood glucose levels and an increased risk of microvascular and macrovascular complications. It commonly develops in adulthood but is increasingly diagnosed in children, adolescents, and younger adults. Major risk factors include overweight or obesity, physical inactivity, advancing age, family history of diabetes, and certain metabolic conditions. Long-term management involves lifestyle modification, glucose-lowering therapies, and regular monitoring to achieve glycemic control and reduce the risk of cardiovascular, kidney, retinal, and neuropathic complications.

Type 2 Diabetes Diagnosis

Type 2 Diabetes is diagnosed through blood glucose testing, including HbA1c, fasting plasma glucose, oral glucose tolerance testing, or random plasma glucose testing in patients with characteristic symptoms. Diagnosis is based on established clinical criteria, with repeat testing generally used to confirm abnormal results in the absence of unequivocal hyperglycemia. Additional assessments may include lipid profile, kidney function, blood pressure, and screening for diabetes-related complications to support comprehensive disease management and treatment planning.

Note: Further details are provided in the report....

Type 2 Diabetes Treatment

The primary goals of Type 2 Diabetes treatment are to achieve and maintain glycemic control, reduce the risk of diabetes-related complications, support healthy weight management, and improve long-term quality of life. Current management includes lifestyle modifications and glucose-lowering therapies, with agents such as semaglutide (OZEMPIC, RYBELSUS), tirzepatide (MOUNJARO), empagliflozin (JARDIANCE), dapagliflozin (FARXIGA), sitagliptin (JANUVIA), and insulin widely used across different stages of disease management. Emerging therapies, including oral metabolic agents, next-generation incretin-based therapies, and multi-receptor agonists such as retatrutide, CagriSema, and survodutide, aim to enhance glycemic control, promote weight loss, and provide broader cardiovascular and kidney benefits while improving treatment convenience and adherence.

Note: Further details related to country-based variations are provided in the report...

Type 2 Diabetes Unmet Needs

The section “unmet needs of Type 2 Diabetes” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Durable and Sustained Glycemic Control

2. Effective and Long-Term Weight Management

3. Comprehensive Cardiovascular and Kidney Protection

4. Improved Treatment Adherence and Patient Convenience, and others…..

Note: Comprehensive unmet needs insights and their strategic implications are provided in the full report....

Type 2 Diabetes Epidemiology

The Type 2 Diabetes epidemiology section provides insights about the historical and current Type 2 Diabetes patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Type 2 Diabetes market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings from Type 2 Diabetes Epidemiological Analysis and Forecast

• According to the Centers for Disease Control and Prevention (CDC), over 38 million Americans around 1 in 10  have diabetes, with 90% to 95% of cases being type 2 diabetes. While it typically develops in adults over 45, an increasing number of children, teens, and young adults are now being diagnosed.
• As per the research study, the prevalence of Type 2 Diabetes in Germany is approximately 9.9%. The prevalence increases sharply from age 50 to 80, with the highest number of new diagnoses occurring around age 85.
• In France, the prevalence of Type 2 Diabetes is 4.6% in the general population, with rates increasing substantially with age. Approximately one in five men aged 70 to 85 years and one in seven women aged 75 to 85 years receive pharmacological treatment for Type 2 Diabetes.
• Using data from the National Health and Nutrition Examination Survey (NHANES), the CDC estimated that 32.7% of US adolescents aged 12–17 years had prediabetes in 2023.

Type 2 Diabetes Epidemiology Segmentation

• Total Prevalent Cases of Type 2 Diabetes
• Total Diagnosed Prevalent Cases of Type 2 Diabetes
• Age-specific Diagnosed Prevalent Cases of Type 2 Diabetes
• Gender-specific Diagnosed Prevalent Cases of Type 2 Diabetes
• Treated Cases of Type 2 Diabetes

Recent Developemnts in the Type 2 Diabetes Treatment Landscape:

• In June 2026, Novo Nordisk reported positive Phase III results from the REIMAGINE 1–3 trials, demonstrating that CagriSema achieved significant reductions in HbA1c and body weight in adults with type 2 diabetes. The findings were presented at the ADA 2026 Scientific Sessions
• In April 2026, Eli Lilly reported positive Phase III ACHIEVE-4 results for orforglipron in adults with type 2 diabetes and overweight/obesity at elevated cardiovascular risk. The trial met its primary endpoint, showing non-inferior MACE risk versus insulin glargine, while delivering greater reductions in A1C and body weight through 104 weeks. All-cause mortality was also lower with FOUNDAYO, although this analysis was not multiplicity-controlled.
• In February 2026, Novo Nordisk announced CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial.

Type 2 Diabetes Drug Chapters & Competitive Analysis

The Type 2 Diabetes drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I–III Type 2 Diabetes clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Type 2 Diabetes treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Type 2 Diabetes therapeutics market.

Approved Therapies for Type 2 Diabetes

Bexagliflozin (BRENZAVVY): TheracosBio

It is a SGLT2 inhibitor approved by the US FDA in January 2023 as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes. By inhibiting SGLT2 in the renal proximal tubule, it reduces glucose reabsorption and lowers the renal threshold for glucose, leading to increased urinary glucose excretion and improved blood sugar control. BRENZAVVY is administered orally. It also stands out as the lowest priced SGLT2 inhibitor currently available in the US market.

Semaglutide (OZEMPIC/RYBELSUS/WEGOVY): Novo Nordisk

Semaglutide is a GLP-1 receptor agonist marketed by Novo Nordisk under different brand names with distinct FDA-approved indications.

• OZEMPIC: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
• RYBELSUS: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for these events.

GLP-1 Agonist Marketed/Approved Therapies

Note: Detailed marketed therapies assessment will be provided in the final report...

Type 2 Diabetes Pipeline Analysis

CagriSema: Novo Nordisk

CagriSema, developed by Novo Nordisk, is a once-weekly subcutaneous fixed-dose combination of the long-acting amylin analogue cagrilintide (2.4 mg) and the GLP-1 receptor agonist semaglutide (2.4 mg). It is being investigated for the treatment of adults with Type 2 Diabetes, with the potential to improve glycemic control and provide additional benefits in body weight and cardiometabolic risk factors.

Survodutide (BI 456906): Boehringer Ingelheim

Survodutide (BI 456906), developed by Boehringer Ingelheim, is a glucagon receptor (GCGR)/GLP-1 receptor dual agonist being evaluated for Type 2 Diabetes. By targeting both receptors, survodutide is designed to enhance glucose control while also supporting weight reduction and broader metabolic improvements. The compound is currently in Phase III development.

Note: A detailed emerging therapies assessment will be provided in the final report...

Type 2 Diabetes Key Players, Market Leaders and Emerging Companies

• TheracosBio
• Novo Nordisk
• Eli Lilly
• Boehringer Ingelheim
• AstraZeneca
• Johnson & Johnson
• Merck, and others.

Type 2 Diabetes Market Outlook

The Type 2 Diabetes treatment landscape is evolving toward a patient-centered, multifaceted approach encompassing lifestyle modification, glucose monitoring, pharmacotherapy, and, in selected patients, metabolic surgery. Lifestyle interventions, including healthy diet, regular physical activity, and weight management, remain the foundation of care; however, the growing prevalence of Type 2 Diabetes and increasing need for durable glycemic control continue to drive demand for pharmacologic therapies. Metformin remains a widely used first-line option, while sulfonylureas, glinides, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin are utilized based on glycemic needs, comorbidities, safety, and patient preferences. The market is increasingly shifting toward therapies that provide benefits beyond glucose lowering, particularly cardiovascular and renal protection and weight reduction, supporting continued uptake of SGLT2 inhibitors and GLP-1 receptor agonists. Emerging combination and multi-agonist therapies are expected to further intensify competition by targeting both glycemic control and metabolic outcomes. Insulin remains an important treatment option for patients with inadequate control despite non-insulin therapies, while continuous glucose monitoring and other digital tools are supporting more personalized treatment optimization. Metabolic surgery also represents an established option for eligible patients with obesity and poorly controlled Type 2 Diabetes. Overall, the Type 2 Diabetes market is expected to be shaped by rising disease burden, increasing treatment intensification, demand for therapies with cardiometabolic benefits, and continued innovation in combination and next-generation therapies.

Note: Further details will be provided in the report...

Drug Class/Insights into Leading Emerging and Marketed Therapies in Type 2 Diabetes (2022–2036 Forecast)

The Type 2 Diabetes treatment landscape comprises therapies targeting multiple pathways involved in glucose regulation, insulin sensitivity, renal glucose handling, and metabolic control. Established therapies include biguanides, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, thiazolidinediones, GLP-1 receptor agonists, and insulin, while emerging therapies increasingly focus on multi-target mechanisms and improved cardiometabolic outcomes.

• Insulin Sensitizers and Insulin Secretagogues: Established therapies such as metformin and pioglitazone improve glycemic control primarily by reducing hepatic glucose production and enhancing insulin sensitivity. Sulfonylureas and glinides stimulate pancreatic insulin secretion and provide effective glucose lowering, although their use may be limited by risks such as hypoglycemia and weight gain.
• Incretin-Based Therapies: DPP-4 inhibitors such as sitagliptin and linagliptin enhance endogenous incretin activity, while GLP-1 receptor agonists such as semaglutide, dulaglutide, and liraglutide provide potent glucose lowering with additional weight-loss and cardiometabolic benefits. Increasing innovation is focused on dual and multi-agonist therapies that simultaneously target multiple metabolic pathways to improve glycemic control and weight management.
• SGLT2 Inhibitors: Agents such as empagliflozin and canagliflozin reduce renal glucose reabsorption, thereby increasing urinary glucose excretion and lowering blood glucose levels. Beyond glycemic control, this class provides important cardiovascular and renal benefits, supporting its growing role in patients with Type 2 Diabetes and associated cardiovascular or kidney disease.

Overall, metformin, SGLT2 inhibitors, and GLP-1 receptor-based therapies remain key pillars of Type 2 Diabetes management, while dual- and multi-target metabolic therapies are driving innovation. The emergence of novel combination therapies and next-generation incretin-based agents is expected to broaden treatment options and potentially reshape the Type 2 Diabetes market by addressing glycemic control, weight management, cardiovascular and renal outcomes, and other persistent unmet needs beyond conventional glucose lowering.

Note: Further details will be provided in the report...

Type 2 Diabetes Drug Uptake

This section focuses on the uptake rate of potential Type 2 Diabetes drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the Type 2 Diabetes market's uptake by drugs, patient uptake by therapy, and sales of each drug.

Note:  Further detailed analysis of emerging therapies' drug uptake in the report...

Market Access and Reimbursement of Type 2 Diabetes

US

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

Note: Further details are provided in the final report...

Type 2 Diabetes Therapies Price Scenario & Trends

Pricing and analogue assessment of Type 2 Diabetes therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Note: Further details are provided in the final report...

Industry Experts and Physician Views for Type 2 Diabetes

To keep up with Type 2 Diabetes market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the Type 2 Diabetes emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in Type 2 Diabetes, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the University of Mississippi Medical Center, University of Bologna, and Teikyo University School of Medicine, etc. were contacted. Their opinion helps understand and validate current and emerging Type 2 Diabetes therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in Type 2 Diabetes.

Type 2 Diabetes Report Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Type 2 Diabetes, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Type 2 Diabetes Market Report

• The report covers a segment of key events, an executive summary, a descriptive overview of Type 2 Diabetes, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Type 2 Diabetes market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Type 2 Diabetes market.

Type 2 Diabetes Market Report Insights

• Type 2 Diabetes Patient Population Forecast
• Type 2 Diabetes Therapeutics Market Size
• Type 2 Diabetes Pipeline Analysis
• Type 2 Diabetes Market Size and Trends
• Type 2 Diabetes Market Opportunity (Current and forecasted)

Type 2 Diabetes Market Report Key Strengths

• Type 2 Diabetes Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year Forecast
• Type 2 Diabetes Market Outlook (North America, Europe, Asia-Pacific)
• Type 2 Diabetes Patient Burden Trends (by geography)
• Type 2 Diabetes Treatment Addressable Market (TAM)
• Type 2 Diabetes Competitive Landscape
• Type 2 Diabetes Major Companies Insights
• Type 2 Diabetes Price Trends and Analogue Assessment
• Type 2 Diabetes Therapies Drug Adoption/Uptake
• Type 2 Diabetes Therapies Peak Patient Share analysis

Type 2 Diabetes Market Report Assessment

• Type 2 Diabetes Current Treatment Practices
• Type 2 Diabetes Unmet Needs
• Type 2 Diabetes Clinical Development Analysis
• Type 2 Diabetes Emerging Drugs Product Profiles
• Type 2 Diabetes Market Attractiveness
• Type 2 Diabetes Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs Related to the Type 2 Diabetes Market Report:

• Type 2 Diabetes Market Insights
• What was the Type 2 Diabetes market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Type 2 Diabetes?
• What are the disease risks, burdens, and unmet needs of Type 2 Diabetes? What will be the growth opportunities across the 7MM concerning the Type 2 Diabetes patient population?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Type 2 Diabetes? What are the current guidelines for treating Type 2 Diabetes in the US, Europe, and Japan?

Reasons to Buy Type 2 Diabetes Market Forecast Report

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Type 2 Diabetes market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)   enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.